전체 8345
-
- Neural Circuits Underlying Somatosensation
-
- - Karel Svoboda, Ph.D., Howard Hughes Medical Institute (2010/11/18)
- - Category : Neuroscience
- Dr. Svoboda is a Group Leader at the Janelia Farm Research Campus of the Howard Hughes Medical Institute. Research in Dr. Svoboda lab focuses on the circuitry and synaptic mechanisms underlying experience-dependent cortical plasticity. By combining molecular techniques, electrophysiology, and innovative optical methods, their work has addressed numerous questions ranging from molecular and cellular mechanisms of synaptic plasticity to cortical circuits and their plasticity in vivo. Recently they have developed techniques for recording and imaging cortical activity in behaving mice and this will be the focus of his lecture in the Neuroscience Seminar Series.
NIH Neuroscience Seminar Series
Neural Circuits Underlying Somatosensation
-
- Recombinant Immunotoxins for the Treatment of B cell Malignancies and Mesothelioma: A Clinical and Laboratory Update (NIH-Only)
-
- - Pastan, Ira H.
National Institutes of Health (U.S.) (2010/11/18) - - Category : NCI CCR Grand Rounds (NIH Only)
- - Pastan, Ira H.
- Dr. Ira Pastan obtained his M.D. from Tufts Medical School.
After serving as house officer at the Yale School of Medicine, he joined NIH and became a clinical associate at the National Institute of Arthritis and Metabolic Diseases (NIAMD), where he carried out thyroid research. He then served as postdoctoral fellow with Earl Stadtman. He then joined the Clinical Endocrinology Branch, NIAMD. Later, he moved to NCI as head of the Molecular Biology Section in the Endocrinology Branch. He established the Laboratory of Molecular Biology at NCI in 1970 and has served as chief of the laboratory since its establishment. Honors and other special scientific recognition include the following: Van Meter Prize, American Thyroid Association; G.
Burroughs Mider Lectureship, NIH; membership, National Academy of Sciences; membership, American Academy of Arts and Sciences; fellow, American Academy of Microbiology; fellow, American Association for the Advancement of Science; Special Achievement Award, Nature Biotechnology Winter Symposium; Outstanding Mentor Award, NCI; NIH Director？？？s Award; DHHS Secretary？？？s Award for Meritorious Service; and the International Antonio Feltrinelli Prize for Medicine. Dr.
Pastan has served as an editor or on the editorial board of Endocrinology, Cell, Journal of Cell Biology, Journal of Biological Chemistry, Experimental Cell Research, Journal of Cellular Physiology, FASEB Journal, Molecular Medicine, Clinical Cancer Research, Molecular Cancer Therapeutics, Apoptosis, and Cancer Genomics & Proteomics. Dr. Pastan？？？s current interest is in developing new therapies for cancer by making fusion proteins composed of the Fv portion of antibodies directed at antigens on cancer cells fused to a genetically modified form of a powerful bacterial toxin, Pseudomonas exotoxin A. These chimeric proteins, which are termed recombinant immunotoxins, are now being tested in humans with various forms of cancer. One of these, BL22, has produced many complete remissions in drug-resistant hairy cell leukemia.
NCI？？？s Center for Cancer Research (CCR) Grand Rounds is a weekly lecture series addressing current research in clinical and molecular oncology. Speakers are leading national and international researchers and clinicians proposed by members of the CCR Grand Rounds Planning Committee and others within the CCR community and approved by the CCR Office of the Director. Lectures occur every Tuesday from 8:00 to 9:00 a.m. in Lipsett Amphitheater in the Clinical Center building on the NIH campus September through July with exceptions around holidays and major cancer meetings. The lecture schedule is posted on various calendars of events, including at the following link: http://bethesdatrials.cancer.gov/health-care-professionals/grand-rounds.aspx.
Recombinant Immunotoxins for the Treatment of B cell Malignancies and Mesothelioma: A Clinical and Laboratory Update (NIH-Only)
-
- Administrative Strategies - Trials and Tribulations: Clinical Studies Overseas (HHS Only)
-
- - NIH (2010/11/18)
- - Category : STEP (HHS Only)
- STEP: Staff Training in Extramural Programs
Are you developing a site for a clinical trial to be conducted abroad? If you are not doing it now, you may be doing it soon. Are you ready for the challenges? Your knowledge and experience of the ethical, regulatory and legal issues may determine the difference between success and failure. Come to this forum to learn the basic steps necessary for navigating the stormy waters of implementing a clinical trial overseas.
Committee Members:- Chair: Carmen Rosa
- Valerie Maholmes
- Valery Gordon
- Blaine Moore
- Dorothy Duke
- Priti Mehrotra
- Barbara Woynarowska
http://odoerdb2-1.od.nih.gov/oer/training/step/step_training_20100413.htm
Administrative Strategies - Trials and Tribulations: Clinical Studies Overseas (HHS Only)
-
- Breast Cancer: Genetic and other Mechanisms
-
- - Lawrence Brody (NHGRI), Kathleen Calzone (NCI) (2010/11/18)
- - Category : Demystifying Medicine
- The course includes presentation of patients, pathology, diagnosis and therapy in the context of major disease problems and current research. Primarily directed toward Ph.D. students, fellows, and staff, it is also of interest to medical students and clinicians. The course is designed to help bridge the gap between advances in biology and their application to major human diseases. Each session includes clinical and basic science components which are presented by NIH staff and outside invitees.
For more information, visit
http://www1.od.nih.gov/oir/DemystifyingMed
Breast Cancer: Genetic and other Mechanisms
-
- Head and Neck Cancer Chemoprevention: Intervention Using Local Delivery Strategies
-
- - Dr. Susan Mallery, The Ohio State University, College of Dentistry (2010/11/18)
- - Category : OCCAM Monthly Lecture Series
- The NCIs Office of Cancer Complementary and Alternative Medicine (OCCAM) invites you to view its monthly lecture series.
With the goal of informing the National Cancer Institute (NCI) community about the variety of ongoing research in cancer and complementary and alternative medicine (CAM), NCIs Office of Cancer Complementary and Alternative Medicine (OCCAM) has created a monthly lecture series on cancer CAM. These hour long lectures, occurring from 10 a.m. - 11 a.m. on the second Wednesday of each month, will feature a fifty minute presentation on a cancer CAM topic and allow ten minutes for questions.
For more information, visit
http://www.cancer.gov/cam/news/monthly-lecture-series.html
Head and Neck Cancer Chemoprevention: Intervention Using Local Delivery Strategies
-
- Lunch and Learn Parenting Seminar: Legal Issues Facing the "Sandwich Generation"
-
- - Barbara E. Bullman, Elder and Family Law, LifeWork Strategies (2010/11/18)
- - Category : Parenting
- A large number of adults today are finding themselves in the ？？？sandwich generation？？？ characterized by those who care for their own children, as well as for their aging parents. The legal aspects of families in this situation can be complex; attend this seminar to learn more about how to prepare for and navigate through this phase of your life. This seminar will cover trust funds, wills, power of attorney, and other important steps you can take today to prepare yourself and your family.
Acrobat Slides
Lunch and Learn Parenting Seminar: Legal Issues Facing the "Sandwich Generation"
-
- Great Teachers: Mysterious Cases
-
- - Mark C. Henderson, MD (2010/11/18)
- - Category : Clinical Center Grand Rounds
- Mark C. Henderson, MD,
Residency Program Director, Department of Internal Medicine,
Associate Dean for Admissions, University of California-Davis, School of Medicine
For more information, visit
http://www.cc.nih.gov/about/news/grcurrent.html
Great Teachers: Mysterious Cases
-
- Proteins as Chameleons: The Good, the Bad and the Ugly
-
- - Dr. Catherine Costello (2010/11/18)
- - Category : Wednesday Afternoon Lectures
- Proteins are not merely the products from gene translation, but may undergo extensive co- and post-translational modifications that result in significant divergence from the plan of the template. And some are not even template-driven! Full understanding of normal and aberrant protein structure/function relationships requires not only identification and quantification of proteins that indicate which cellular pathways are affected under the conditions chosen for study, but also characterization of post-translational modifications (PTMs) to these proteins [1]. Antibody-based pull-down methods retrieve molecular complexes whose composition can vary depending on the presence of sequence elements or PTMs of key proteins [2]. Alternatively, chemical modifications to specific amino acids (e.g., ICAT, fluorolabels) or isolation methods that are based on chemical interactions (e.g., with phosphate groups) enable the enrichment of proteins/peptides that bear specific markers for processes such as oxidative stress, protein misfolding, or cancer [1-6]. We have developed strategies for separation of intact proteins or peptides and for determination of their complete amino acid sequences and the identification and site-specific localization of PTMs. If the PTMs are labile under routine MS conditions (e.g., phosphorylation, sulfonation, glycosylation), particular attention needs to be paid to the selection of dissociation conditions that preserve and, ultimately, fully define the modification(s). When individual proteins have multiple PTMs, only analysis of the intact proteins will provide information on the correlations between PTMs. Isolated proteins may be subjected to proteolytic or chemical degradation (bottom-up ？？？) or analyzed in their intact form (top-down ？？？). Examples from recent and ongoing projects will be presented to illustrate some of the proteomic and glycomic strategies developed and utilized in our Center to catch the elusive chameleons.
The NIH Directors Wednesday Afternoon Lecture Series includes weekly scientific talks by some of the top researchers in the biomedical sciences worldwide.
Proteins as Chameleons: The Good, the Bad and the Ugly
-
- Human Embryonic Stem Cells (hESC): The Scientific Promise and Grants Managements Role (HHS-Only)
-
- - Sponsored by GMAC Subcommittee on Training (2010/11/18)
- - Category : GMAC (HHS Only)
- The NIH is beginning to fund awards that involve the use of human embryonic stem cell lines (hESC) approved under the new 2009 NIH Guidelines. An increasing number of lines now appear on the NIH Human Embryonic Stem Cell as eligible for use by NIH grantees in NIH funded research. NIH must maintain precise records about the use of hESCs in awards. Seminar will educate font-line GM Staff regarding responsibilities, processes and actions required to ensure all systems contain accurate data about hESC awards, as well as reflection of appropriate hESC language within Notices of Award.
http://odoerdb2-1.od.nih.gov/gmac/gmac/trs_main.html
Human Embryonic Stem Cells (hESC): The Scientific Promise and Grants Managements Role (HHS-Only)
-
- DDM Seminar - Lessons on Authentic Leadership (NIH-Only)
-
- - Betsy Myers, Senior Advisor to Barack Obamas Presidential Campaign (2010/11/18)
- - Category : DDM Seminar Series (NIH Only)
- Click here to respond to a Survey about this DDM Seminar. Information will be used to evaluate the program and improve future seminars.
On behalf of Colleen Barros, Deputy Director for Management (DDM), the NIH Training Center is pleased to announce the third seminar of the 2009 - 2010 DDM Seminar Series featuring Betsy Myers. She will address the NIH community in a presentation on inclusive leadership entitled Lessons on Authentic Leadership
Betsy Myers most recently served as a senior advisor to Barack Obama？？？s presidential campaign. She joined the campaign in January 2007 as the chief operating officer and is known for instilling the campaign with a business operational model and customer service mentality. Myers also represented the campaign as Chair of Women for Obama. She traveled extensively in 2008 speaking to voters and concentrating on women？？？s outreach. These efforts included a working partnership with Women for Obama and the DNC？？？s Women？？？s Leadership Forum. Prior to this appointment, Myers was the executive director of the Center for Public Leadership (CPL) at Harvards Kennedy School of Government. She came to CPL in 2003, bringing with her a proven track record of building, growing, funding and strategically realigning organizations. Motivated by her strong belief that the hardest person we will ever manage is ourselves, Myers is known for bringing a focus to the Centers teaching and research around personal leadership and the fully integrated person. She also increased the Center？？？s efforts around women and leadership and worked closely with the Harvard？？？s Women？？？s Leadership Board (2000-2007).
During her presentation, Betsy Myers will use examples from her various roles in government and private sector to demonstrate that the days of "command and control" approach to leadership has given way to a new era, one of inclusive leadership. Myers will use recent data from research studies including: The Diversity Theorum, Glass Ceiling Report, and the new Deloitte Report, to support the necessity of inclusive leadership.
Topics Include:- What is Inclusive Leadership?
- Building Relationships
- Generational, Cultural and Personality Impact
- The Disconnected Worker and What it Means to an Organization
- Navigating an Organization While Remaining Effective and Positive
- Your Authentic Self
DDM Seminar - Lessons on Authentic Leadership (NIH-Only)
-
- Biospecimens and Biorepositoies Resources
-
- - NIH Biospecimen Interest Group (2010/11/18)
- - Category : Biospecimens
- A series of presentations on biospecimen resources within the NIH and supported by the NIH.
NIH Biospecimen Interest Group
Biospecimens and Biorepositoies Resources
-
- Reducing Cancer Risk in Health Care Settings
-
- - Dr. Sue Curry (2010/11/18)
- - Category : Crosstalk Lectures
- Crosstalk Lecture Series
The goal of the "Crosstalk" Lecture Series is to engage researchers whose work explicitly translates theory and/or methods from one literature or topic area (e.g., obesity) to another (e.g., tobacco cessation). ？？？Crosstalk？？？ is part of a Behavioral Research Program (Division of Cancer Control and Population Sciences, National Cancer Institute) initiative to expand connections between, and among, behavioral science disciplines ？？？ both in our own work and in that of our constituency.
Reducing Cancer Risk in Health Care Settings
-
- NIH Directors Council of Public Representatives - April 2010
-
- - NIH (2010/11/18)
- - Category : NIH Directors Council of Public Representatives
- The Directors Council of Public Representatives (COPR) is a federal advisory committee made up of members of the public, who advise the National Institutes of Health (NIH) Director on issues related to public participation in NIH activities, outreach efforts, and other matters of public interest.
For more information, visit
http://copr.nih.gov
NIH Directors Council of Public Representatives - April 2010
-
- Targeted Immunotherapy for Treatment of Malignant Mesothelioma
-
- - Dr. Raffit Hassan, Laboratory of Molecular Biology, NCI (2010/11/18)
- - Category : NIH Directors Seminars
- Directors Seminar Series
Over the last several years our work has focused on the development and clinical evaluation of immunotoxins targeting mesothelin-expressing tumors. Mesothelin is a 40-kDa glycosylphosphatidylinositol (GPI)- linked cell surface glycoprotein that is present on normal mesothelial cells and overexpressed in several tumors especially ovarian cancers, mesotheliomas and pancreatic cancer. Our laboratory studies have shown it to be a promising target for cancer therapy. Since the murine anti-mesothelin monoclonal antibody K1 by itself is not cytotoxic towards mesothelin positive cells, we have developed immunotoxins targeting mesothelin using the potent bacterial toxin, Pseudomonas exotoxin (PE). This toxin consists of three functional domains: the cell binding domain that allows binding to a cell surface protein, the translocation domain that brings an active fragment of the toxin to the cytosol and the ADP-ribosylation domain that inhibits protein synthesis leading to cell death. For making immunotoxins we use a mutated 38 kDa fragment of PE termed PE38, lacking the cell binding domain that can be replaced by a targeting moiety such as the Fv portion of an antibody. SS1(dsFv)PE38 (SS1P), is a recombinant immunotoxin consisting of the anti-mesothelin Fv (obtained by phage display) linked to PE38.
Based on the in vitro and in vivo activity of SS1P and toxicological studies in cynomolgus monkeys, SS1P was approved by the FDA for clinical evaluation in patients. Currently, we are conducting a Phase I clinical trial of SS1P in mesothelin positive tumors at the NCI and 23 patients have been treated thus far. Completion of this Phase I clinical trial will provide valuable information regarding the maximum tolerated dose, dose limiting toxicities, immunogenicity, pharmacokinetics as well as anti-tumor activity of SS1P. Following completion of the Phase I study, we plan to conduct Phase II studies, to evaluate the anti-tumor activity of SS1P in specific tumor types expressing mesothelin. Since greater than 900f mesotheliomas and pancreatic tumors express mesothelin, and there are no effective treatments for these diseases, conduct of phase II studies of SS1P in these tumor types will be a priority.
Targeted Immunotherapy for Treatment of Malignant Mesothelioma
-
- MYH9 and Kidney Disease ？？？ Day 1
-
- - NIDDK (2010/11/18)
- - Category : Conferences
- In 2008, two teams of researchers identified variations in a single gene, MYH9, that are strongly associated with kidney diseases disproportionately affecting African Americans. MYH9 risk variants account for nearly all of the increased risk for idiopathic focal segmental glomerulosclerosis (FSGS) and HIV-associated FSGS among African Americans compared to European Americans and a portion of the increased risk for hypertensive kidney disease. Surprisingly, however, these variants were not associated with kidney failure arising from diabetes.
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) will convene a conference entitled MYH9 and Kidney Disease: Clinical and Public Health Implications of Recent Genetic Findings in Populations on April 19-20, 2010, in Bethesda, MD, in partnership with the National Center on Minority Health and Health Disparities (NCMHD), National Human Genome Research Institute (NHGRI), National Heart, Lung and Blood Institute (NHLBI), National Cancer Institute (NCI), Centers for Disease Control and Prevention (CDC), and Office of Behavioral and Social Sciences Research (OBSSR). The conference will review genetic, public health, and ethical and social implications of these new findings, and conference participants will provide feedback to the National Institutes of Health (NIH) regarding future research directions. The conference will focus on: (1) possible further basic science and genetic studies; (2) public health approaches; and (3) important questions regarding screening and social and ethical ramifications of the findings and public health recommendations in the U.S. population. Goals of the conference are to: ？？？ Review the current state of knowledge related to the clinical utility, public health implications, and future research needs after identification of MYH9 loci as a factor associated with genetic susceptibility to non-diabetic kidney disease, including hypertensive nephrosclerosis, focal segmental glomerulosclerosis, and HIV-associated nephropathy; ？？？ Stimulate research and clinical application in this area; ？？？ Foster the development of multi-specialty collaborations; and ？？？ Provide recommendations to NIDDK for future research in advancing this field.
MYH9 and Kidney Disease ？？？ Day 1
-
- Strategic Directions for the Future of CAM and Integrative Medicine Research: A Dialogue with the NIH Community
-
- - Dr. Josephine P. Briggs, Director of NCCAM, NIH (2010/11/18)
- - Category : NCCAM Lectures
- The Complementary and Integrative Medicine Consult Service lecture series sponsored by NCCAM provides NIH clinical center staff with the opportunity to learn more about how the integration of various complementary and alternative medicine treatments can affect approaches in the research and practice for medicine.
Strategic Directions for the Future of CAM and Integrative Medicine Research: A Dialogue with the NIH Community
-
- Lexinome, Proteome, Ima*Genome? New Views of Dyslexia
-
- - Jeffery Gruen, M.D., Yale University, School of Medicine (2010/11/18)
- - Category : Neuroscience
- Dr. Gruen？？？s primary research interest involves finding and characterizing genes that cause reading disability, commonly known as dyslexia. Dyslexia is present in 10 to 20% of school children and is the most common cause of learning disability. It is also mostly genetic in origin with genetic factors accounting for 40% to 60% of the poor performance in reading tests. Through genetic studies of families and children with dyslexia, his group identified a major contributing gene, doublecortin-domain-containing-2 (DCDC2) (Meng et al, PNAS 102: 17053-17058, 2005). Moreover, he showed that a deletion in a putative regulatory sequence in DCDC2 is present in ~20% of dyslexics. He has now found 20 variations (alleles) of this regulatory (enhancer) sequence and is working on identifying which alleles are the most deleterious and which may be protective, and how these variations functionally alter brain development using immunocytochemistry, RNAi, a mouse knockout model, and other molecular approaches in animals. His group is also exploring how variations of DCDC2 and other dyslexia genes alter brain activation patterns in human subjects using functional magnetic resonance imaging (fMRI), and brain cytoarchitecture using voxel-based morphometry analyses of gray matter and fractional anisotropy.
A neonatologist by training, Dr. Gruen also studies genetic contributions to common disorders encountered in prematurely born infants. Using heritability analyses of identical and non-identical twins born less than 32 weeks gestational age, he and collaborators found that genetic factors account for at least 45% of the variance in liability for bronchopulmondary dysplasia, a common pediatric form of chronic lung disease (Bhandari et al, Pediatrics, 117(6):1901-1906, 2006), 70% of the variance for retinopathy of prematurity (Bizzarro et al, Pediatrics, 118(5):1858-1863, 2006), and 70% of the variance for the most common congenital heart disease, patent ductus arteriosus (PDA).
NIH Neuroscience Seminar Series
Lexinome, Proteome, Ima*Genome? New Views of Dyslexia
-
- MYH9 and Kidney Disease ？？？ Day 2
-
- - NIDDK (2010/11/18)
- - Category : Conferences
- In 2008, two teams of researchers identified variations in a single gene, MYH9, that are strongly associated with kidney diseases disproportionately affecting African Americans. MYH9 risk variants account for nearly all of the increased risk for idiopathic focal segmental glomerulosclerosis (FSGS) and HIV-associated FSGS among African Americans compared to European Americans and a portion of the increased risk for hypertensive kidney disease. Surprisingly, however, these variants were not associated with kidney failure arising from diabetes.
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) will convene a conference entitled MYH9 and Kidney Disease: Clinical and Public Health Implications of Recent Genetic Findings in Populations on April 19-20, 2010, in Bethesda, MD, in partnership with the National Center on Minority Health and Health Disparities (NCMHD), National Human Genome Research Institute (NHGRI), National Heart, Lung and Blood Institute (NHLBI), National Cancer Institute (NCI), Centers for Disease Control and Prevention (CDC), and Office of Behavioral and Social Sciences Research (OBSSR). The conference will review genetic, public health, and ethical and social implications of these new findings, and conference participants will provide feedback to the National Institutes of Health (NIH) regarding future research directions. The conference will focus on: (1) possible further basic science and genetic studies; (2) public health approaches; and (3) important questions regarding screening and social and ethical ramifications of the findings and public health recommendations in the U.S. population. Goals of the conference are to: ？？？ Review the current state of knowledge related to the clinical utility, public health implications, and future research needs after identification of MYH9 loci as a factor associated with genetic susceptibility to non-diabetic kidney disease, including hypertensive nephrosclerosis, focal segmental glomerulosclerosis, and HIV-associated nephropathy; ？？？ Stimulate research and clinical application in this area; ？？？ Foster the development of multi-specialty collaborations; and ？？？ Provide recommendations to NIDDK for future research in advancing this field.
MYH9 and Kidney Disease ？？？ Day 2
-
- Chromatin Responses to DNA Damage
-
- - Xuetong Shen, M.D., Anderson, Smithville (2010/11/18)
- - Category : DNA Repair
- The DNA Repair Interest Group is concerned with all forms of DNA damage and repair. As a major defense against environmental damage to cells DNA repair is present in all organisms examined including bacteria, yeast, drosophila, fish, amphibians, rodents and humans. The members of the DNA Repair Interest Group perform research in areas including DNA repair enzymology and fine structure, mutagenesis, gene and cell cycle regulation, protein structure, and human disease.
Acrobat Slides
For more information, visit the
DNA Repair Interest Group
Chromatin Responses to DNA Damage
-
- Diabetes: Autoimmunity and Therapeutic Challenges
-
- - Abner Louis Notkins (NIDCR), Jean-Marc Guettier (NIDDK) (2010/11/18)
- - Category : Demystifying Medicine
- The course includes presentation of patients, pathology, diagnosis and therapy in the context of major disease problems and current research. Primarily directed toward Ph.D. students, fellows, and staff, it is also of interest to medical students and clinicians. The course is designed to help bridge the gap between advances in biology and their application to major human diseases. Each session includes clinical and basic science components which are presented by NIH staff and outside invitees.
For more information, visit
http://www1.od.nih.gov/oir/DemystifyingMed
Diabetes: Autoimmunity and Therapeutic Challenges